By Sabela Ojea
Shares of Northwest Biotherapeutics on Friday dropped after the company said it had delayed the submission of its marketing application for its glioblastoma treatment in the U.K.
At 12:02 E.T., shares were down 7.9%, at 73 cents.
The biotechnology company said it still has to finalize the last key section of its marketing application to the Medicines and Healthcare Products Regulatory Agency for the commercial approval of its immune therapy DCVax.
Glioblastoma is a fast-growing and aggressive brain tumor.
Northwest Biotherapeutics now expects to submit the application between mid to late November.
Write to Sabela Ojea at [email protected]
Read the full article here